The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses a single-center study investigating haploidentical stem cell transplantation (haplo-SCT) with non-myeloablative conditioning and post-transplant cyclophosphamide (PTCy) in patients over the age of 70 with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (HR-MDS). The study shows favorable outcomes, with over 70% overall survival (OS) at two years. Dr Devillier also questions age as a barrier to transplantation, emphasizing the need to evaluate each patient individually, considering biological age and frailty in treatment decisions. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
